SCHEMBL5335331

SCHEMBL5335331

COc1ccc(COP(=O)(O)OCc2ccc(OC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
AKR1C3 P42330 1/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 2/20 0.53
MAPT P10636 1/20 0.53
IDO1 P14902 2/20 0.52
AGXT P21549 2/20 0.52
CALM1 P0DP23 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
PLA2G4B P0C869 1/20 0.46
ANPEP P15144 1/20 0.46
ERAP2 Q6P179 1/20 0.46
FFAR1 O14842 1/20 0.46
APP P05067 1/20 0.46
LDHA P00338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16815024 0.93 TSHR (0.53) TSHRAKR1C3NPC1RAB9APOLB
SCHEMBL16812902 0.89 ALDH1A1 (0.58) TSHRAKR1C3NPC1RAB9APOLB
SCHEMBL8389200 0.89 NPC1 (0.53) NPC1RAB9APOLBSMN1; SMN2ALDH1A1
SCHEMBL8049409 0.82 IDO1 (0.53) NPC1RAB9APOLBSMN1; SMN2ALDH1A1
SCHEMBL27595468 0.81 IDO1 (0.57) NPC1RAB9APOLBSMN1; SMN2ALDH1A1
SCHEMBL20840419 0.81 IDO1 (0.57) NPC1RAB9APOLBSMN1; SMN2ALDH1A1
SCHEMBL28467953 0.80 TSHR (0.55) TSHRAKR1C3NPC1RAB9APOLB
SCHEMBL9138537 0.80 TSHR (0.64) TSHRAKR1C3NPC1RAB9AALDH1A1
SCHEMBL31326220 0.79 TSHR (0.69) TSHRAKR1C3IDO1CA2
SCHEMBL1369690 0.79 IDO1 (0.50) NPC1RAB9APOLBSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235666-B2 Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent CILAG LTD. (CH) 2007-06-26 US claimed
US-7235666-B2 Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent CILAG LTD. (CH) 2007-06-26 US disclosed
US-20050272706-A1 Process for the preparation of sodium fosphenytoin CILAG, LTD. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272706-A1 Process for the preparation of sodium fosphenytoin FOS, DUSP5, DCPS TSHR 3700/4885AKR1C3 1482/4885NPC1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.